ArticlePloS one2025
Oral cancer in Hungary: An epidemiological profile (2015-2019).
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHungary is among countries with the highest standardised rate oral and mouth cancers. This first national analysis aimed to quantify age-standardized oral cancer incidence in Hungary from 2015 to 2019 by sex and age, determine the median interval from diagnosis to death, and evaluate comorbidity prevalence and its prognostic impact.
methodsWe used real-world data from the Hungarian National Health Insurance Fund database. Adjusted, standardised incidence- and hospital readmission rates were calculated; time between diagnosis and death and effect of comorbidities coexisting with oral cancer were analysed.
resultsGenerally, incidence and hospitalisation rates decreased in the studied period, for males and older age group both rates were higher. From year 2017 for incidence rates significant differences were found between a particular region and the other regions; and hospitalisation rates differed significantly for three regions from other regions. Almost half (46.3%) of the patients died within a year after diagnosis, mortality rates were 31.8% for males and 14.5% for females. Existence of oral cancer indicated 5.20 (95% confidence interval, 5.03,5.38), 5.84 (95% confidence interval, 5.64,6.04) odd ratios for mortality by two models. Number and relative risk of comorbidities were higher among patients diagnosed with oral cancer than in the control population.
conclusionThe study highlighted progress in reducing oral cancer incidence rates in Hungary, however significant challenges remain in reducing mortality rates and improving survival within the first year of diagnosis. The study also showed oral cancer a serious burden in the country, especially for males.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.